Pretreatment radiomic imaging features combined with immunological indicators to predict targeted combination immunotherapy response in advanced hepatocellular carcinoma

Table 2 Univariate and multivariate analyses of factors predicting therapeutic efficacy (n = 56)

Clinicopathologic variable	OR	95%CI	P value
Univariate analysis
Age	5.308	0.594-47.429	0.135
HBV infection	2.280	0.675-7.705	0.185
AFP	1.000	1.000-1.000	0.433
Vascular invasion	0.680	0.231-2.001	0.484
Ascites	0.918	0.315-2.679	0.876
RER	0.029	0.006-0.128	0.000a
ALBI	1.400	0.070-28.120	0.826
NLR	26.600	6.314-112.054	0.000a
PLR	7.222	2.148-24.288	0.001a
PNI	3.667	1.108-12.137	0.033a
Multivariate analysis
NLR group (< 5 vs ≥ 5)	21.765	1.231-384.877	0.036a
PLR group (< 300 vs ≥ 300)	33.857	1.261-909.284	0.036a
PNI group (< 45 vs ≥ 45)	73.367	1.362-3951.454	0.035a
RER group (< 9 vs ≥ 9)	187.23	2.007-17464.635	0.024a

^aP < 0.05. OR: Odds ratio; CI: Confidence interval; HBV: Hepatitis B virus; RER: Relative enhancement ratio; ALBI: Albumin-bilirubin; NLR: Neutrophil to lymphocyte ratio; PLR: Platelet to lymphocyte ratio; PNI: Prognostic nutrition index.